Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06532773 · ClinicalTrials.gov registry record · NA
Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment
A NA study of Hematologic Malignancy, sponsored by Duke University.
- Recruiting
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06532773 is a NA study of Hematologic Malignancy that is actively recruiting participants, run by Duke University. The registered enrollment target is 60 participants, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06532773, a NA study of Hematologic Malignancy, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
People with hematologic cancer often have sleep disturbance and symptoms of fatigue, stress, and pain. This study is being done to test a mindfulness intervention for sleep disturbance and symptom management in patients with hematologic cancer during and after inpatient treatment (Nite2Day+). Participants will complete a baseline survey online, using a mobile application, or paper/pencil. Once the baseline survey is complete, participants will be randomized (like a flip of a coin) to receive Nite2Day+ or Standard Care. Nite2Day+ will include activities during and after inpatient treatment. During inpatient treatment, participants will use a mobile app to access: 1) mindfulness meditations, 2) brief sleep education videos, and 3) brief videos teaching strategies to improve sleep quality in the hospital. After inpatient treatment, participants will complete 6, videoconference sessions (45-60 minutes) with a trained therapist to learn mindfulness and behavioral coping strategies to self-manage nighttime sleep disturbance and daytime symptoms of fatigue, stress, and pain. Three follow-up surveys will occur at hospital discharge, and approximately 8, and 12 weeks after hospital discharge. Participants randomized to Nite2Day+ will be given the option to complete an exit interview to provide feedback on the Nite2Day+ program. Participants randomized to Standard Care will only complete the four surveys. All participants will continue to receive their usual medical care. The total study duration is about 16 weeks.
Conditions Studied
Interventions
- BEHAVIORAL Nite2Day+
Study Locations (1)
North Carolina
- 2400 Pratt Street - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-01-06 |
| Est. Completion | 2029-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06532773
The ClinicalTrials.gov registry entry for NCT06532773 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 227-participant average among 48 other Hematologic Malignancy trials with a reported enrollment target (74% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hematologic Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Nite2Day+ is the first listed.
NCT06532773 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06532773 about?
NCT06532773 is a clinical study titled "Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment". People with hematologic cancer often have sleep disturbance and symptoms of fatigue, stress, and pain. This study is being done to test a mindfulness intervention for sleep disturbance and symptom management in patients with hematologic cancer during and after inpatient treatment (Nite2Day+). Partic...
What is the current status of trial NCT06532773?
This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2026-01-06. Estimated completion is 2029-06.
What conditions does trial NCT06532773 study?
This clinical trial studies the following conditions: Hematologic Malignancy.
What interventions are being tested in trial NCT06532773?
The interventions under investigation include: Nite2Day+ (BEHAVIORAL).
Who is sponsoring clinical trial NCT06532773?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06532773 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
RECRUITING · NA
-
Implementation of an Oral Chemotherapy Adherence Intervention
RECRUITING · NA
-
ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period
RECRUITING · NA
-
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
-
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.